European Companies Search Engine
EU funding (€172,750): Unraveling redox regulation in cancer stem cells as a potential therapeutic target for breast cancer Hor4 Sept 2022 EU Research and Innovation programme "Horizon"
Overview
Text
Unraveling redox regulation in cancer stem cells as a potential therapeutic target for breast cancer
ABSTRACT Breast cancer (BC) is the most frequently diagnosed cancer and the first cause of cancer death in women worldwide. In many tumors, including BC, there is a population of cancer stem cells (CSCs) characterized for unlimited self-renewal and being resistant to conventional cancer therapies eventually leading to tumor relapses and metastases. Breast CSCs (BCSCs) show high cellular plasticity and are capable of shifting between a proliferative epithelial-like (E) state and a quiescent mesenchymal-like (M) state. This plasticity of BCSCs facilitates their ability to initiate and grow primary tumors, invade the basement membrane, traverse tissue vasculature, and ultimately colonize distant organs to form clinically significant metastases. It has been recently proposed that redox regulation might play a significant role in BCSCs plasticity and aggressiveness. We hypothesize that the redox-regulated BCSC plasticity and the highly oxidative metabolism of E-BCSCs might be a vulnerability that could be exploited as a novel BC therapy. We aim to characterize BCSCs in terms of individual ROS production, transducing our breast cancer patient-derived organoids (PDOs) collection with genetically-encoded redox sensors. We will treat breast cancer PDOs with conventional chemotherapy and inhibitors of PI3K to study changes in redox signaling occurring in the tumor. Finally, we will attempt to target these cells and modulate their redox regulation in order to differentiate and eliminate them. We expect to better understand the redox-regulation of BCSCs, to subsequently modulate BCSC redox state to target and eliminate these cells, increasing conventional therapy effectiveness and decreasing the minimal residual disease and cancer spread in BC patients, contributing to overall survival.
Funded Companies:
| Company name | Funding amount |
| UNIVERSITAT DES SAARLANDES | ? |
| Universita Degli Studi Di Torino | €172,750 |
Source: https://cordis.europa.eu/project/id/101068377
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Universitat des Saarlandes, Saarbrücken, Germany.
The visualizations for "UNIVERSITAT DES SAARLANDES - EU funding (€172,750): Unraveling redox regulation in cancer stem cells as a potential therapeutic target for breast cancer"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
